well the fact that an insider exercised options is a good thing too. we wait to see. hopefully at the conference some institutions see the potential and jump on board.
interesting to note (i guess seeking alpha last Oct 2009 article was right on--Link: http://seekingalpha.com/instablog/401845... you compare the mkt cap of some of the medical device Co's that applied for FDA approval like IMGG ( a co that has been seeking fda approval going on 2 yrs, yes 2 years)their mkt cap on about 376,000,000 million o/s is ~$260,000,000 MILLION...for a machine that cost over $500,000. *****THIS GIVES GTHP A PPS OF ~$13.33 ***** on an equivalent basis
if you take gthp o/s of about 19.5 Mil ((( funny this is only about 13.1 mil more than the recent high flyer Vermilion-VRML-PPS $29.75, O/S of ~6.4 Mil , authorized 150 Mil-MARKET CAP OF $191,000,000 MILLION,"note shares went from .04 cents to $1.04 in one day" ) *****this gives gthp a pps over $3.50***** on equiv basis
so fair value for gthp i guess lies between $3.50--13.33 pps, this was a quick analysis, but given whats occuring in the current mkt environment for biotech breakthroughs & new technology it is reflective of current valuations (personally i believe it will be much higher than $13.33 given the broad mkt spectrum & breakthrough technology), can anyone say "beam me up Scotty". Long
News 
Market Data 
Discover 
AI
